Synergetic B-cell Immunomodulation in SLE - 2nd Study.
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
In follow-up of the previous SynBioSe Study the present study is a randomized controlled
trial designed to further investigate the long-term clinical and imunological efficacy of
combination B-cell targeting by starting treatment with belimumab (anti-BAFF) followed by
rituximab(anti-CD20) in lupus nephritis patients.